Vir Biotechnology Shares Drop 13% Following Announcement of Proposed Public Offering
Vir Biotechnology (VIR) shares fell approximately 13% on Thursday after the company announced its intention to conduct an underwritten public offering of common stock. The move aims to raise capital through the sale of new shares to investors. To provide additional flexibility, Vir Biotechnology has granted underwriters a 30-day option to purchase up to an additional 15% of the offered shares. Such offerings typically lead to immediate share price dilution, which often triggers selling pressure from existing shareholders.
Tickers: $VIR